Twist Bioscience stock falls 5% despite beating fourth quarter estimates
Twist Bioscience (TWST) reported Q4 2026 earnings beating estimates with $126.6M revenue and adjusted EPS of -$0.32. Shares fell 5.42% premarket. Q1 2027 guidance of $130M-$132M revenue exceeds consensus. Full-year 2026 revenue hit $459.4M, up 22% YoY. CEO highlights growth, margin expansion, and positive adjusted EBITDA.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise expectations for continued growth, but the immediate market reaction was negative, suggesting investors are weighing margin and cash‑flow sustainability.
Market read
Twist Bioscience's earnings and guidance are the primary drivers of the stock's 5% pre‑market decline, with potential spillover to the broader biotech sector.
What to watch
Strong cash position ($582 M) and positive adjusted EBITDA may provide runway for future growth, which could be undervalued in the current sell‑off.
Background
Twist Bioscience, a synthetic DNA manufacturer, posted Q4 FY2026 results that beat revenue and EPS estimates and provided FY2027 guidance above consensus.
Ticker impact
Shares fell 5.42% pre‑market after Twist Bioscience reported Q4 beat and raised FY2027 revenue guidance above estimates.
likely continued downside pressure as the market digests the guidance and margin expectations
Guidance beat but stock dropped 5% pre‑market, indicating investors are skeptical; the guidance range is modest and margin outlook is only slightly improved.
Market effects
Synthetic‑biology sector may see heightened scrutiny of guidance versus earnings beats.
US biotech/health‑tech stocks could experience modest pullback amid cautious investor sentiment.
Limited; impact confined to US‑listed biotech and related ETFs.
Counterpoint
The earnings beat and raised guidance could support a short‑term bounce if the market overreacts to the pre‑market sell‑off.
Key entities
- ExecutiveEmily M. Leproust
CEO and co‑founder of Twist Bioscience, quoted on the earnings release.
